Italy29 September 2022

MSG Congress

23rd Muscle Study Group Meeting

Share this page


Octapharma is proud to support the Muscle Study Group (MSG) 2022 Meeting

The Muscle Study Group (MSG), is a consortium of scientific investigators from academic and research centers who are committed to the cooperative planning, implementation, analysis and reporting of controlled clinical trials and of other research for muscle and other neuromuscular diseases.

23rd Annual Muscle Study Group Scientific Meeting will be held in Stresa, Lake Maggiore, Italy from September 30th to October 2nd, 2022.

Click here to learn more about Muscle Study Group

Through this page, you will access detailed information about Octapharma most recent Phase III clinical studies with IVIG in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Dermatomyositis (DM), as well as some additional insights on Dermatomyositis and our IVIG products, panzyga® and octagam®, now approved for the treatment of CIDP and DM respectively.

Octapharma sponsored clinical studies

Read more on this page to learn about two recent Octapharma sponsored clinical studies focusing on treating Chronic Inflammatory Demyelinating Polyneuropathy and Active Dermatomyositis:

ProDERM Trial

Efficacy, Tolerability and Safety of IVIg (octagam® 10%) in Adult Patients with Active Dermatomyositis

Dermatomyositis is a rare, idiopathic autoimmune disorder, with patients commonly suffering from skin rashes, chronic muscle inflammation and progressive muscle weakness.

The ProDERM study was a double-blind, placebo-controlled randomised trial that investigated the efficacy and safety of octagam® 10% in adults with dermatomyositis. A significantly higher proportion of the patients randomised to octagam® 10% showed a response to treatment compared with the placebo group in the initial 16-week period (79% vs 44%, p=0.0008).

Based on the results from the phase ProDERM study, the U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis.

Octagam® 10% has also been approved for the treatment of dermatomyositis in the EU and is indicated for use in adults with active dermatomyositis treated with immunosuppressive drugs, including corticosteroids, or with intolerance or contraindications to those drugs. 

Learn more about the ProDERM trial

Watch Prof. Rohit Aggarwal, Medical Director of the Arthritis and Autoimmunity Center at the University of Pittsburgh School of Medicine and a member of the ProDERM study Steering Committee, providing insights on the study

ProCID Trial

Efficacy and Safety of IVIG in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune mediated neuropathy characterised by progressive weakness and impaired sensory function in the limbs.

The ProCID study was a prospective, double-blind, randomised, multi-centre phase III study that assessed the efficacy and safety of Panzyga® in patients with CIDP and compared two different maintenance dosages of Panzyga® (a higher one of 2.0 g/kg and a lower one of 0.5 g/kg) with the standard dosing scheme of 1.0 g/kg every 3 weeks. The results of the study confirmed the efficacy of Panzyga® in adults with CIDP at the standard dose of 1.0 g/kg every 3 weeks. Almost 80% (55/69) of patients responded to treatment with a decrease of at least 1 point in the adjusted inflammatory neuropathy cause and treatment (INCAT) disability score by the end of the 24-week treatment period. Results also suggested a dose response with a greater proportion of patients responding with increasing doses of Panzyga®.

Learn more about the ProCID trial

Watch Dr. Kadar, investigator in the ProCID trial, providing insights on the study

The information provided on this page is intended for healthcare professionals attending the Muscle Study Group Meeting 2022 only.

The information on this page has been developed for an international audience. Accordingly, this page may contain information on products and/or indications that are not approved in your country. Please refer to your country-specific approved product labelling for important safety information and always consult your country-specific product information before prescribing, as product registrations and approved indications may vary from country to country.

Octagam®10% is licensed in Italy under the trade name "Gamten"

Share this page